shr-8068
mAbexperimental
Clinical trial activity
20 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
10
Phase 2
19
Phase 3
3
Phase 4
0
Earliest trial started Aug 1, 2022 (NCT05444088)
Timeline
Indications
Studied for
Mechanism of action
- Cytotoxic T-lymphocyte protein 4INHIBITOR
CTLA4 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07266025 | Phase 2 | Jan 30, 2026 | Fudan University |
| NCT07239596 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2025 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT07229625 | Phase 3 | Nov 30, 2025 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT07071714 | Phase 2 | Jul 22, 2025 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT07028281 | Phase 2 | Jul 8, 2025 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT06859775 | Phase 1/Phase 2 (Phase 2) | Mar 31, 2025 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT06844474 | Phase 2 | Mar 7, 2025 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT06778031 | Phase 2 | Feb 26, 2025 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT06754930 | Phase 1/Phase 2 (Phase 2) | Feb 18, 2025 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT06703177 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2024 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT06639347 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2024 | Hengrui Therapeutics, Inc. |
| NCT06618664 | Phase 3 | Oct 30, 2024 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT06589778 | Phase 1/Phase 2 (Phase 2) | Sep 27, 2024 | Hengrui Therapeutics, Inc. |
| NCT06465563 | Phase 2 | Jul 2, 2024 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT06434103 | Phase 1/Phase 2 (Phase 2) | Jun 30, 2024 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT06373133 | Phase 1/Phase 2 (Phase 2) | May 1, 2024 | Sichuan University |
| NCT06335355 | Phase 2/Phase 3 (Phase 3) | Mar 31, 2024 | Government of China |
| NCT06247956 | Phase 2 | Mar 11, 2024 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT05416775 | Phase 1/Phase 2 (Phase 2) | Aug 15, 2022 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT05444088 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2022 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
Showing 20 of 20 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | For profit | 15 | 15 | 2 | 2022 |
| Hengrui Therapeutics, Inc. | For profit | 2 | 2 | 1 | 2024 |
| Fudan University | Academic/Hospital | 1 | 1 | 1 | 2026 |
| Government of China | Government | 1 | 1 | 1 | 2024 |
| Sichuan University | Academic/Hospital | 1 | 1 | 1 | 2024 |
5 organizations
Page 1 / 1